Login / Signup

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.

Christelle De La FouchardièreDavid MalkaClaire CropetSylvie ChabaudJudith RaimbourgDamien BotsenSimon LaunayLudovic EvesqueAngélique VienotHervé PerrierMarine JaryYves RinaldiClélia CoutzacJean Baptiste BachetCindy NeuzilletNicolas WillietRomain DesgrippesThomas GrainvilleThomas AparicioAnnie PeytierThierry LecomteGaël S RothAnne Thirot-BidaultNicolas LachauxOlivier BoucheFrançois Ghiringhelli
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
While GEMPAX did not meet the primary end point of OS versus gemcitabine alone in patients with mPDAC in the second-line setting, both PFS and ORR were significantly improved.
Keyphrases
  • phase iii
  • locally advanced
  • open label
  • clinical trial
  • squamous cell carcinoma
  • small cell lung cancer
  • double blind
  • phase ii
  • placebo controlled
  • randomized controlled trial
  • radiation therapy
  • rectal cancer